Harvard Apparatus Regenerative Technology Inc.

OTC: HRGN · Healthcare · Biotechnology

PublicHQ Holliston, MACIK 0001563665Reports USD

#897 of 1,394 Healthcare companies by revenuetop-quartile growth

EA Score

42D

FH 28DQ 61GM —SS 45

v0.1 · 55/100 weight · provisional

↑ disclosure history, revenue growth (YoY) · ↓ return on equity, Altman-Z

Methodology →

Revenue TTM

$445.0k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$6.9M

Employees

Market cap

$18.3M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$704.0k$704.0k2025

Net income-$6.9M-$6.9M2025

Operating income-$6.9M-$6.9M2025

Total assets$2.7M$2.7M2025

Liabilities$1.6M$1.6M2025

Equity$1.1M$1.1M2025

Revenue trend

FY2017 – FY2025 · USD

FY17

FY18

FY19

FY21

$103.0k

FY23

$430.0k

FY24

$704.0k

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Harvard Apparatus Regenerative Technology Inc. booked $704.0k in FY2025 revenue, growing 64% year over year — faster than most Healthcare companies we track, at a -975.7% net margin.

Peers · Healthcare

Neuphoria Therapeutics Inc.44D Atossa Therapeutics, Inc.29D DIAGNOS Inc.29D Defence Therapeutics Inc.——

Key facts

CEOJunli He

SectorHealthcare

IndustryBiotechnology

HeadquartersHolliston, MA

ExchangeOTC: HRGN

Employees8

IPO date2013-10-21

Latest filings

8-K2026-06-24 10-Q2026-05-13 8-K2026-04-28 DEF 14A2026-04-23 8-K2026-04-15 10-K2026-03-19 8-K2026-01-06 10-Q2025-11-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.